News

FDA placed clinical hold on Gilead HIV treatment trials of GS-1720
The Food and Drug Administration has placed a clinical hold on Gilead’s (GILD) HIV treatment trials of GS-1720 and/or GS-4182 ...
Fierce Biotech4d
FDA slaps clinical hold on multiple Gilead HIV combo therapy trials, shares fall
Gilead has been hit with a clinical hold from the FDA for five tests of its experimental HIV combination treatment amid ...
FDA Places Clinical Hold on Gilead's HIV Studies, Stock Down
GILD slides 2.6% after FDA halts trials for HIV candidates, GS-1720 and GS-4182, over safety concerns in patients.
Clinical Trials Arena on MSN3d
Gilead hit with FDA clinical hold for batch of HIV trials
Decreasing CD4 and lymphocyte counts in some participants receiving an oral combination therapy led to holds in the study.
Medical Dialogues3d
USFDA places clinical hold on Gilead Sciences trials testing HIV pill combination
Gilead Sciences has announced that the U.S. Food and Drug Administration has placed a clinical hold on its HIV treatment ...
MPR3d
FDA Puts Clinical Hold on Gilead’s Trials for Two HIV Drug Candidates
Gilead’s HIV treatment trials involving an investigational integrase strand inhibitor (GS-1720) and an investigational capsid inhibitor (GS-4182) have been put on clinical hold by the Food and Drug ...
Stocktwits on MSN4d
US FDA Places Clinical Hold On Gilead Trials Of Two Investigational HIV Treatments: Retail’s On The Fence
Shares of Gilead Sciences, Inc. (GILD) traded over 1% lower on Tuesday noon after the company said that the U.S. Food and ...
Why Gilead Scinces Stock Tumbled on Tuesday
On some negative news about one of its investigational programs, the stock of pharmaceutical company Gilead Sciences (NASDAQ: ...
The Pharma Letter3d
Gilead’s HIV combo trials halted by FDA amid safety concerns
Gilead Sciences has paused five clinical trials of its investigational HIV drugs GS-1720 and GS-4182 after the American medicines regulator raised safety concerns. The once-weekly oral regimen was ...
Morningstar4d
Gilead: FDA Places Clinical Hold on HIV Treatment Trials of GS-1720, GS-4182
Gilead Sciences said the U.S. Food and Drug Administration has placed a clinical hold on studies of an investigational weekly HIV pill combination over signs of potentially weakened immune systems ...
The Motley Fool4d
Why Gilead Scinces Stock Tumbled on Tuesday
The regulator ordered the company to pause its current trials of the pair, GS-1720 and GS-4182, after some participants were found to have low levels of CD4+ T-cells (a type of white blood cell).